Compare · NVS vs TYRA
NVS vs TYRA
Side-by-side comparison of Novartis AG (NVS) and Tyra Biosciences Inc. (TYRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and TYRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $306.26B, about 221.5x TYRA ($1.38B).
- NVS has been more active in the news (5 items in the past 4 weeks vs 4 for TYRA).
- NVS has more recent analyst coverage (25 ratings vs 21 for TYRA).
- Company
- Novartis AG
- Tyra Biosciences Inc.
- Price
- $160.53+0.17%
- -
- Market cap
- $306.26B
- $1.38B
- 1M return
- +6.79%
- -
- 1Y return
- +22.07%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 21
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Tyra Biosciences Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
Latest TYRA
- SEC Form 10-Q filed by Tyra Biosciences Inc.
- Tyra Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
- Tyra Biosciences to Participate in Upcoming Investor Conferences
- SEC Form SCHEDULE 13G filed by Tyra Biosciences Inc.
- President and CEO Harris Todd was granted 864 shares, increasing direct ownership by 0.06% to 1,438,495 units (SEC Form 4)
- Vice President, Finance (PAO) Rueb Yuliya was granted 2,925 shares, increasing direct ownership by 35% to 11,258 units (SEC Form 4)
- Chief Financial Officer Fuhrman Alan was granted 951 shares, increasing direct ownership by 3% to 37,115 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Tyra Biosciences Inc.
- SEC Form 4 filed by Director Ra Capital Management, L.P.